{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-24-000007","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.925739+00:00","generated_at":"2026-06-05T06:44:57.113031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre Q4 2023 net loss $63.2M; cash $339.6M; pipeline on track with SPY001 FIH H1 2024","bullets":["Net loss $63.2M in Q4 2023 vs $18.8M in Q4 2022; cash $339.6M as of Dec 31, 2023.","Raised $180M gross from private placement; cash runway into H2 2026.","SPY001 anti-α4β7 shows 22-day half-life (3x vedolizumab); FIH studies expected H1 2024 with interim data year-end.","SPY002 anti-TL1A candidates nominated; preclinical half-life 24 days (2-3x clinical-stage); FIH in H2 2024.","Appointed CEO Cameron Turtle and board member Mark McKenna; name changed to Spyre Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-24-000007","json":"https://secwatch.observer/filing/0001636282-24-000007.json","markdown":"https://secwatch.observer/filing/0001636282-24-000007.md","text":"https://secwatch.observer/filing/0001636282-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/0001636282-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/agle-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:44:57.113031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b481180c5e14378311391bcd1bdacc338090a81","claim":"Spyre Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628224000007/0001636282-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}